Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Eve Of House Hearing, FDA Makes Its Case For LDT Framework

This article was originally published in The Gray Sheet

Executive Summary

The agency details 20 case studies to support its planned framework for regulating laboratory-developed tests in a report issued the day before a House subcommittee held a hearing on alternative legislative schemes.

Advertisement

Related Content

Diagnostics Reg Overhaul Floated In US House
What's Next For LDTs? FDA May Be Eyeing A New Game Plan
In Case You Missed It: Top 10 "Gray Sheet" Stories In November
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
Califf Supports Combo Products Pathway At Confirmation Hearing
House Diagnostics Reg Reform Draft Proposes Pathways For Relaxed Scrutiny

Topics

Advertisement
UsernamePublicRestriction

Register

MT034395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel